Experimental treatment for solid tumors with specific gene changes
Part of Brain & nervous system, Lungs & breathing, Mental health, Skin clinical trials.
This trial tests a new drug that targets tumors with certain gene changes, which may help stop cancer growth. It is for people whose cancer has not improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- Your cancer must have a specific gene change that the study is looking for
- Your cancer must have grown or come back after at least one standard treatment
- You must be able to give a tissue sample from your tumor for testing
- You must not have had certain other cancer treatments within a specific time before joining
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
This trial tests a new drug, SSS59, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and how it affects the body.
This trial tests a new drug called SSGJ-709 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
This Phase 1/2 trial tests SGN1 in people with advanced solid tumors whose cancer has grown despite standard treatments, or who could not tolerate them. The study aims to find a safe dose and see whether the drug can work in certain cancer types.
This trial tests a new drug called SSGJ-706, either alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed. The goal is to see if it helps shrink or control the cancer.
This study tests a new medicine (called GB261) given as an infusion for people with systemicsclerosis (scleroderma) that affects the skin widely. The goal is to see if it can reduce skin thickening and improve symptoms.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.